Expanding the potential therapeutic options of hemoperfusion in the era of improved sorbent biocompatibility
Open Access
- 31 May 2023
- journal article
- review article
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 42 (3) , 298-311
Abstract
Hemoperfusion has been considered a promising adjuvant treatment for chronic diseases and some acute states when specific removal of pathogenic factors from the bloodstream is desired. Over the years, advances in adsorption materials (e.g., new synthetic polymers, biomimetic coating, and matrixes with novel structures) have renewed scientific interest and expanded the potential therapeutic indications of hemoperfusion. There is growing evidence to suggest a prominent place for hemoperfusion as an adjuvant treatment in the setting of sepsis or severe coronavirus disease 2019 and as a therapeutic option for chronic complications associated with accumulated uremic toxins in patients with end-stage renal disease. This literature review will describe the principles, therapeutic perspectives, and the emerging role of hemoperfusion as a complementary therapy for patients with kidney disease.Keywords
This publication has 95 references indexed in Scilit:
- Cardiovascular Burden Associated with Uremic Toxins in Patients with Chronic Kidney DiseaseAmerican Journal of Nephrology, 2013
- Adsorption of Doxorubicin on Poly(methyl methacrylate)–Chitosan–Heparin-Coated Activated Carbon BeadsLangmuir, 2012
- Cytokine Adsorbing Columns2010
- Adsorbents with High Selectivity for Uremic Middle Molecular Peptides Containing the Asp-Phe-Leu-Ala-Glu SequenceLangmuir, 2010
- Ultralow‐Fouling, Functionalizable, and Hydrolyzable Zwitterionic Materials and Their Derivatives for Biological ApplicationsAdvanced Materials, 2010
- Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic reviewCritical Care, 2007
- Review on uremic toxins: Classification, concentration, and interindividual variabilityKidney International, 2003
- Adsorbents: From Basic Structure to Clinical Application2002
- In vitro Studies of the Efficacy of Reversed Phase Silica Gel as a Sorbent for Hemo- and PlasmaperfusionJournal of Toxicology: Clinical Toxicology, 1992
- A New DNA Immune Adsorbent for Hemoperfusion in SLE Therapy: A Clinical TrialArtificial Organs, 1988